The British Business Bank has announced a significant commitment of £100 million to Apposite Healthcare Growth I, a newly established fund designed to bolster the growth of health technology companies based in the UK. This marks the Bank’s largest investment to date and its inaugural partnership with Apposite Capital, a specialist in healthcare and life sciences investing.
Apposite Healthcare Growth I is focused on providing support to innovative firms across various key sub-sectors. The fund aims to tackle the existing deficit of scale-up capital for UK life sciences companies that are on the verge of substantial growth milestones. By investing in businesses that are pioneering technologies and services to enhance patient outcomes, the fund seeks to position them for global competition while fostering high-skilled job creation domestically.
The cornerstone £100 million investment aligns with the broader strategy of the British Business Bank to develop more robust sources of scale-up funding. As the leading investor in UK venture capital and venture growth capital funds, the Bank routinely makes cornerstone investments to help funds reach a successful first close, thereby equipping them with the necessary resources to implement their investment strategies effectively.
The British Business Bank is poised to significantly enhance its backing of UK scale-ups, aiming to direct over 60 percent of its venture and growth investments toward this crucial business stage. Furthermore, the Bank plans to facilitate the establishment of 10 new market-entry growth-stage funds over the next five years by committing larger investments to prominent fund managers.
Christine Hockley, managing director and co-head of funds at the British Business Bank, emphasized the strategic necessity of this capital infusion. “The UK needs growth stage funding, and the Bank is stepping up to deliver this,” she stated. Hockley highlighted the Bank’s collaboration with the UK’s venture capital community to foster the development of growth-stage funds capable of substantial investments in the next generation of UK unicorns.
In addition, Hockley noted that by making larger commitments and signaling these investments to institutional investors, the Bank intends to stimulate private sector participation and equip these funds with the needed resources.
Mark Andrews, investment director of funds and life sciences at the British Business Bank, underscored the distinct challenges faced by the life sciences sector. “The need for scale-up funding is especially pronounced in life sciences,” Andrews pointed out, adding that many promising firms in this field struggle due to a lack of later-stage funding, which forces them into suboptimal or premature exits.
Sam Gray, managing partner at Apposite Capital, regards this investment as a crucial driver for transformative growth within the sector. “The UK is home to an extraordinary depth of scientific research, entrepreneurial talent, and innovative companies, yet many businesses face a persistent gap in scale-up funding,” Gray remarked. He noted that the fund would bridge this gap, allowing high-potential firms to accelerate growth, commercialize groundbreaking technologies, and improve health outcomes while contributing to economic growth.
The initiative has also received strong support from the government. Peter Kyle, Secretary of State for Business and Trade, asserted that this investment fulfills the commitment to support the UK’s most ambitious enterprises. “This record investment into Apposite Capital delivers on that promise by giving it the financial firepower to support the UK’s most exciting healthcare tech firms scale, develop cutting-edge medical products and diagnostics, and improve healthcare right across the country,” Kyle stated.